Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy

Trial Profile

A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2018

At a glance

  • Drugs MCY-M11 (Primary)
  • Indications Adenocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Sponsors MaxCyte
  • Most Recent Events

    • 10 Oct 2018 According to a MaxCyte media release, MaxCyte Commences Dosing in this study.
    • 30 Aug 2018 Status changed from not yet recruiting to recruiting.
    • 01 Aug 2018 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top